* . *
  • About
  • Advertise
  • Privacy & Policy
  • Contact
Monday, June 16, 2025
Earth-News
  • Home
  • Business
  • Entertainment
    Elisabeth Moss’ ‘Handmaid’s Tale’ Emmy chances, by the numbers – Yahoo

    Elisabeth Moss’ ‘Handmaid’s Tale’ Emmy chances, by the numbers – Yahoo

    ‘Gangs of London’ Producer Explains Season 3 Deaths, Hypes Season 4 – Citizen Tribune

    Gangs of London’ Producer Reveals Shocking Season 3 Deaths and Teases Exciting Season 4

    The Iconic Missouri Diner That Gives You A Taste Of Live Entertainment With Your Meal – Yahoo

    Savor Delicious Meals While Enjoying Live Entertainment at Missouri’s Iconic Diner

    Keke Palmer Revealed How She Came Up With Her Son Leodis’ Name – Yahoo

    Keke Palmer Shares the Heartwarming Story Behind Her Son Leodis’ Name

    The Media and Entertainment Deal Machine Is Revving Up – WSJ

    The Media and Entertainment Deal Machine Is Gearing Up for Action

    Op-Ed: Data Storage and Protection in Today’s Media & Entertainment Industry – Sports Video Group

    How Data Storage and Protection Are Transforming the Media & Entertainment Industry

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    Further Upside For Aeries Technology, Inc (NASDAQ:AERT) Shares Could Introduce Price Risks After 27% Bounce – simplywall.st

    Further Upside For Aeries Technology, Inc (NASDAQ:AERT) Shares Could Introduce Price Risks After 27% Bounce – simplywall.st

    Editor’s Pick: 9 Books on Technology – The Gospel Coalition

    9 Must-Read Books That Will Completely Transform How You Understand Technology

    New Semiconductor Technology Could Supercharge 6G Delivery – SciTechDaily

    Revolutionary Semiconductor Technology Set to Turbocharge 6G Connectivity

    UTC To Host Quantum Technology Workshop June 23-25 – Chattanoogan.com: Breaking News

    Join the Quantum Technology Workshop This June 23-25!

    Rimac Technology Powers the Bugatti Tourbillon with Cutting-Edge Battery and Powertrain Tech – Rimac Newsroom

    Rimac Technology Drives the Bugatti Tourbillon with Revolutionary Battery and Powertrain Innovation

    “Co-creation” boosts commercial technology for dual-use defense applications – Breaking Defense

    “Co-creation” boosts commercial technology for dual-use defense applications – Breaking Defense

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
  • Home
  • Business
  • Entertainment
    Elisabeth Moss’ ‘Handmaid’s Tale’ Emmy chances, by the numbers – Yahoo

    Elisabeth Moss’ ‘Handmaid’s Tale’ Emmy chances, by the numbers – Yahoo

    ‘Gangs of London’ Producer Explains Season 3 Deaths, Hypes Season 4 – Citizen Tribune

    Gangs of London’ Producer Reveals Shocking Season 3 Deaths and Teases Exciting Season 4

    The Iconic Missouri Diner That Gives You A Taste Of Live Entertainment With Your Meal – Yahoo

    Savor Delicious Meals While Enjoying Live Entertainment at Missouri’s Iconic Diner

    Keke Palmer Revealed How She Came Up With Her Son Leodis’ Name – Yahoo

    Keke Palmer Shares the Heartwarming Story Behind Her Son Leodis’ Name

    The Media and Entertainment Deal Machine Is Revving Up – WSJ

    The Media and Entertainment Deal Machine Is Gearing Up for Action

    Op-Ed: Data Storage and Protection in Today’s Media & Entertainment Industry – Sports Video Group

    How Data Storage and Protection Are Transforming the Media & Entertainment Industry

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    Further Upside For Aeries Technology, Inc (NASDAQ:AERT) Shares Could Introduce Price Risks After 27% Bounce – simplywall.st

    Further Upside For Aeries Technology, Inc (NASDAQ:AERT) Shares Could Introduce Price Risks After 27% Bounce – simplywall.st

    Editor’s Pick: 9 Books on Technology – The Gospel Coalition

    9 Must-Read Books That Will Completely Transform How You Understand Technology

    New Semiconductor Technology Could Supercharge 6G Delivery – SciTechDaily

    Revolutionary Semiconductor Technology Set to Turbocharge 6G Connectivity

    UTC To Host Quantum Technology Workshop June 23-25 – Chattanoogan.com: Breaking News

    Join the Quantum Technology Workshop This June 23-25!

    Rimac Technology Powers the Bugatti Tourbillon with Cutting-Edge Battery and Powertrain Tech – Rimac Newsroom

    Rimac Technology Drives the Bugatti Tourbillon with Revolutionary Battery and Powertrain Innovation

    “Co-creation” boosts commercial technology for dual-use defense applications – Breaking Defense

    “Co-creation” boosts commercial technology for dual-use defense applications – Breaking Defense

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
Earth-News
No Result
View All Result
Home Health

Bayer to present new Kerendia™ (finerenone) data from comprehensive clinical trial program across a broad range of patients with chronic kidney disease and type 2 diabetes

July 14, 2023
in Health
Bayer to present new Kerendia™ (finerenone) data from comprehensive clinical trial program across a broad range of patients with chronic kidney disease and type 2 diabetes
Share on FacebookShare on Twitter

Berlin, June 3, 2022, – Bayer will present new renal and cardiovascular data from the comprehensive Kerendia™ (finerenone) clinical trial program at the 2022 American Diabetes Association (ADA) 82nd Scientific Sessions. This new data will comprise of further insights from FIDELITY, including late-breaking data from a new post-hoc analysis, as well as retrospective findings from FIDELIO-DKD and FIGARO-DKD. The prespecified pooled analysis FIDELITY, including the Phase III studies FIDELIO-DKD and FIGARO-DKD, comprises the largest Phase III cardiorenal outcomes clinical trial program investigating cardiorenal outcomes in more than 13,000 patients with CKD and T2D.

Kerendia FIDELITY study data:

Data from a new post-hoc analysis from FIDELITY will investigate the effect of finerenone by baseline HbA1c categories, HbA1c variability, and diabetes duration in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Despite well-controlled blood glucose levels and blood pressure, many patients with CKD and diabetes still progress to loss of kidney function. New strategies are needed to prevent further end-organ damage and slow patient’s rate of decline in kidney function.

· Effects of Finerenone in Patients with CKD and T2D Are Independent of HbA1c at Baseline, HbA1c Variability, and Duration of Diabetes
o 16-LB – Late Breaking Poster Session 
o June 5, 2022; 12:00 – 1:00pm (CT) / 7:00 – 8:00pm (CEST)
In addition, a new subgroup analysis of FIDELITY will be presented, evaluating the effects of finerenone on kidney and cardiovascular (CV) outcomes by use of glucagon-like peptide-1 receptor agonists (GLP-1RA) at baseline. This analysis encompasses a larger population including patients with earlier stages of CKD than was included in the previously presented subgroup analysis by GLP-1RA use from the FIDELIO-DKD trial.

· Finerenone in Patients across the Spectrum of CKD and T2D by GLP-1RA Use
o 22-OR – Oral Presentation 
o June 3, 2022; 5:30 – 5:45pm (CT) / June 4, 2022; 12:30 – 12:45am (CEST)

Finerenone FIDELIO-DKD & FIGARO-DKD study data:

Bayer will present new exploratory data from FIDELIO-DKD and FIGARO-DKD, investigating the effects of finerenone on the development of vision-threatening complications in patients with diabetic retinopathy (DR). 

· Effect of Finerenone on Occurrence of Vision-Threatening Events in Patients with DR
o 826-P – General Poster Session 
o June 5, 2022; 12:00 – 1:00pm (CT) / 7:00 – 8:00pm (CEST) 

About Kerendia™ (finerenone)
Kerendia is a non-steroidal, selective mineralocorticoid receptor (MR) antagonist that has been shown to block harmful effects of MR overactivation. MR overactivation contributes to CKD progression and cardiovascular damage which can be driven by metabolic, hemodynamic or inflammatory and fibrotic factors. 
Based on the results of the FIDELIO-DKD Phase III study, Kerendia was granted marketing authorization in the European Union in February 2022 and was approved by the U.S. Food and Drug Administration (FDA) in July 2021. Based on the results of both pivotal Phase III studies, FIDELIO-DKD and FIGARO-DKD, Kerendia was approved in March 2022 by the Japanese Ministry of Health, Labour, and Welfare (MHLW). Finerenone has also been submitted for marketing authorization in multiple other countries worldwide and these applications are currently under review. 

The Phase III study program with finerenone, FINEOVATE, currently comprises five Phase III studies, FIDELIO-DKD, FIGARO-DKD, FINEARTS-HF, FIND-CKD, and FIONA, as well as the Phase II study CONFIDENCE.

About Chronic Kidney Disease in Type 2 Diabetes
Chronic kidney disease (CKD) is a common and potentially deadly condition that is widely underrecognized. CKD progresses silently and unpredictably, with many symptoms not appearing until the disease is well-advanced. CKD is one of the most frequent complications arising from diabetes and is also an independent risk factor of cardiovascular disease. Up to 40% of all patients with type 2 diabetes (T2D) develop CKD. Despite guideline-directed therapies, patients with CKD and T2D remain at high risk of CKD progression and cardiovascular events. It is estimated that CKD affects more than 160 million people with T2D worldwide. CKD and T2D is the main cause of end stage kidney disease, which requires dialysis or a kidney transplant to stay alive. Patients with CKD and T2D are three times more likely to die from a cardiovascular-related cause than those with T2D alone.

About Bayer’s Commitment in Cardiovascular and Kidney Diseases
Bayer is an innovation leader in the area of cardiovascular diseases, with a long-standing commitment to delivering science for a better life by advancing a portfolio of innovative treatments. The heart and the kidneys are closely linked in health and disease, and Bayer is working in a wide range of therapeutic areas on new treatment approaches for cardiovascular and kidney diseases with high unmet medical needs. The cardiology franchise at Bayer already includes a number of products and several other compounds in various stages of preclinical and clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cardiovascular diseases are treated.

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. R&D expenses before special items amounted to 5.3 billion euros. For more information, go to www.bayer.com.

Forward-Looking Statements 
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Bayer.com – https://www.bayer.com/media/en-us/bayer-to-present-new-kerendiatm-finerenone-data-from-comprehensive-clinical-trial-program-across-a-broad-range-of-patients-with-chronic-kidney-disease-and-type-2-diabetes/

Tags: BayerhealthPresent
Previous Post

BlueRock Therapeutics Announces Completion of Enrollment of Phase 1 Trial in Patients with Parkinson’s Disease

Next Post

Safaricom to strengthen spark venture with new venture capital arms

NCSE welcomes Britt Miller – National Center for Science Education

NCSE welcomes Britt Miller – National Center for Science Education

June 16, 2025
Science is on the federal chopping block and North Carolinians will suffer – NC Newsline

Federal Science Funding Slashed: How North Carolinians Will Be Impacted

June 16, 2025
Does yard work count as exercise? UI expert provides tips to maintain a healthy lifestyle during busy summer months – Iowa Now

Is Yard Work Really Exercise? Expert Tips for Staying Healthy During Busy Summer Months

June 16, 2025
Insurers must promote the blue economy – Eco-Business

Insurers must promote the blue economy – Eco-Business

June 16, 2025
Elisabeth Moss’ ‘Handmaid’s Tale’ Emmy chances, by the numbers – Yahoo

Elisabeth Moss’ ‘Handmaid’s Tale’ Emmy chances, by the numbers – Yahoo

June 16, 2025
Tariffs Are Driving 2026 Health Insurance Premiums Up – KFF

Tariffs Are Driving 2026 Health Insurance Premiums Up – KFF

June 16, 2025
Minnesota, Known for Bipartisan Civility, Reels After Attack on Lawmakers – The New York Times

Minnesota, Known for Bipartisan Civility, Reels After Attack on Lawmakers – The New York Times

June 16, 2025
FDA Grants Sarepta Therapeutics Platform Technology Designation to Expedite Gene Therapy Reviews – geneonline.com

FDA Accelerates Gene Therapy Reviews with Breakthrough Platform Technology for Sarepta Therapeutics

June 16, 2025
Grading Auburn sports in 2024-25: How we saw football stack up in latest athletic calendar – Montgomery Advertiser

Auburn Sports 2024-25: Breaking Down the Football Season’s Biggest Highlights

June 16, 2025
Brain development in a facultatively social allodapine bee aligns with caste, but not group living – Frontiers

Brain development in a facultatively social allodapine bee aligns with caste, but not group living – Frontiers

June 16, 2025

Categories

Archives

June 2025
MTWTFSS
 1
2345678
9101112131415
16171819202122
23242526272829
30 
« May    
Earth-News.info

The Earth News is an independent English-language daily published Website from all around the World News

Browse by Category

  • Business (20,132)
  • Ecology (688)
  • Economy (703)
  • Entertainment (21,606)
  • General (15,411)
  • Health (9,744)
  • Lifestyle (708)
  • News (22,149)
  • People (705)
  • Politics (710)
  • Science (15,921)
  • Sports (21,202)
  • Technology (15,690)
  • World (683)

Recent News

NCSE welcomes Britt Miller – National Center for Science Education

NCSE welcomes Britt Miller – National Center for Science Education

June 16, 2025
Science is on the federal chopping block and North Carolinians will suffer – NC Newsline

Federal Science Funding Slashed: How North Carolinians Will Be Impacted

June 16, 2025
  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

Go to mobile version